Juan Marta-Enguita1,2, Manuel Navarro-Oviedo2, Idoia Rubio-Baines1, Nuria Aymerich1, Maria Herrera1, Beatriz Zandio1, Sergio Mayor1, Jose-Antonio Rodriguez2,3, Jose-Antonio Páramo2,3, Estefania Toledo4,5, Maite Mendioroz1,6, Roberto Muñoz1, Josune Orbe7,8. 1. Neurology Department, Complejo-Hospitalario de Navarra, Pamplona, Spain. 2. Atherothrombosis Laboratory, Program of Cardiovascular Diseases, CIMA-Universidad de Navarra, IdiSNA, Pio-XII, 55, 31008, Pamplona, Spain. 3. CIBERCV, ISCIII, Madrid, Spain. 4. Preventive Medicine and Public Health Department, Universidad de Navarra, IdiSNA, Pamplona, Spain. 5. CIBEROBN, ISCIII, Madrid, Spain. 6. Neuroepigenetics Laboratory-Navarrabiomed, Complejo-Hospitalario de Navarra, Universidad Pública de Navarra-UPNA, IdiSNA, Pamplona, Spain. 7. Atherothrombosis Laboratory, Program of Cardiovascular Diseases, CIMA-Universidad de Navarra, IdiSNA, Pio-XII, 55, 31008, Pamplona, Spain. josuneor@unav.es. 8. CIBERCV, ISCIII, Madrid, Spain. josuneor@unav.es.
Abstract
BACKGROUND: Inflammatory response plays an important role in many processes related to acute ischemic stroke (AIS). Calprotectin (S100A8/S100A9), released by monocytes and neutrophils, is a key protein in the regulation of inflammation and thrombosis. The purpose of this study is to evaluate the association of circulating calprotectin with other inflammatory biomarkers and AIS prognosis, as well as the calprotectin content in stroke thrombi. METHODS: Among the 748 patients treated at a comprehensive stroke center between 2015 and 2017, 413 patients with confirmed acute ischemic injury were prospectively evaluated. Patients with systemic inflammation or infection at onset were excluded. Plasma calprotectin was measured by ELISA in blood samples of AIS patients within the first 24 h. Univariate and multivariate logistic regression models were performed to evaluate its association with mortality and functional independence (FI) at 3 months (defined as modified Rankin Scale < 3) and hemorrhagic transformation (HT) after ischemic stroke. Further, S100A9 was localized by immunostaining in stroke thrombi (n = 44). RESULTS: Higher calprotectin levels were associated with 3-month mortality, HT, and lower 3-month FI. After adjusting for potential confounders, plasma calprotectin remained associated with 3-month mortality [OR (95% CI) 2.31 (1.13-4.73)]. Patients with calprotectin ≥ 2.26 μg/mL were 4 times more likely to die [OR 4.34 (1.95-9.67)]. Addition of calprotectin to clinical variables led to significant improvement in the discrimination capacity of the model [0.91 (0.87-0.95) vs 0.89 (0.85-0.93); p < 0.05]. A multimarker approach demonstrated that patients with increased calprotectin, CRP, and NLR had the poorest outcome with a mortality rate of 42.3% during follow-up. S100A9 protein, as part of the heterodimer calprotectin, was present in all thrombi retrieved from AIS patients. Mean S100A9 content was 3.5% and tended to be higher in patients who died (p = 0.09). Moreover, it positively correlated with platelets (Pearson r 0.46, p < 0.002), leukocytes (0.45, p < 0.01), and neutrophil elastase (0.70, p < 0.001) thrombus content. CONCLUSIONS: Plasma calprotectin is an independent predictor of 3-month mortality and provides complementary prognostic information to identify patients with poor outcome after AIS. The presence of S100A9 in stroke thrombi suggests a possible inflammatory mechanism in clot formation, and further studies are needed to determine its influence in resistance to reperfusion.
BACKGROUND: Inflammatory response plays an important role in many processes related to acute ischemic stroke (AIS). Calprotectin (S100A8/S100A9), released by monocytes and neutrophils, is a key protein in the regulation of inflammation and thrombosis. The purpose of this study is to evaluate the association of circulating calprotectin with other inflammatory biomarkers and AIS prognosis, as well as the calprotectin content in stroke thrombi. METHODS: Among the 748 patients treated at a comprehensive stroke center between 2015 and 2017, 413 patients with confirmed acute ischemic injury were prospectively evaluated. Patients with systemic inflammation or infection at onset were excluded. Plasma calprotectin was measured by ELISA in blood samples of AIS patients within the first 24 h. Univariate and multivariate logistic regression models were performed to evaluate its association with mortality and functional independence (FI) at 3 months (defined as modified Rankin Scale < 3) and hemorrhagic transformation (HT) after ischemic stroke. Further, S100A9 was localized by immunostaining in stroke thrombi (n = 44). RESULTS: Higher calprotectin levels were associated with 3-month mortality, HT, and lower 3-month FI. After adjusting for potential confounders, plasma calprotectin remained associated with 3-month mortality [OR (95% CI) 2.31 (1.13-4.73)]. Patients with calprotectin ≥ 2.26 μg/mL were 4 times more likely to die [OR 4.34 (1.95-9.67)]. Addition of calprotectin to clinical variables led to significant improvement in the discrimination capacity of the model [0.91 (0.87-0.95) vs 0.89 (0.85-0.93); p < 0.05]. A multimarker approach demonstrated that patients with increased calprotectin, CRP, and NLR had the poorest outcome with a mortality rate of 42.3% during follow-up. S100A9 protein, as part of the heterodimer calprotectin, was present in all thrombi retrieved from AIS patients. Mean S100A9 content was 3.5% and tended to be higher in patients who died (p = 0.09). Moreover, it positively correlated with platelets (Pearson r 0.46, p < 0.002), leukocytes (0.45, p < 0.01), and neutrophil elastase (0.70, p < 0.001) thrombus content. CONCLUSIONS: Plasma calprotectin is an independent predictor of 3-month mortality and provides complementary prognostic information to identify patients with poor outcome after AIS. The presence of S100A9 in stroke thrombi suggests a possible inflammatory mechanism in clot formation, and further studies are needed to determine its influence in resistance to reperfusion.
Authors: Alejandro Bustamante; Elena López-Cancio; Sara Pich; Anna Penalba; Dolors Giralt; Teresa García-Berrocoso; Carles Ferrer-Costa; Teresa Gasull; María Hernández-Pérez; Mónica Millan; Marta Rubiera; Pedro Cardona; Luis Cano; Helena Quesada; Mikel Terceño; Yolanda Silva; Mar Castellanos; Moisés Garces; Silvia Reverté; Xavier Ustrell; Rafael Marés; Joan Josep Baiges; Joaquín Serena; Francisco Rubio; Eduardo Salas; Antoni Dávalos; Joan Montaner Journal: Stroke Date: 2017-07-17 Impact factor: 7.914
Authors: Johannes Schindelin; Ignacio Arganda-Carreras; Erwin Frise; Verena Kaynig; Mark Longair; Tobias Pietzsch; Stephan Preibisch; Curtis Rueden; Stephan Saalfeld; Benjamin Schmid; Jean-Yves Tinevez; Daniel James White; Volker Hartenstein; Kevin Eliceiri; Pavel Tomancak; Albert Cardona Journal: Nat Methods Date: 2012-06-28 Impact factor: 28.547
Authors: Maria Karolina Jonsson; Nina Paulshus Sundlisæter; Hilde Haugedal Nordal; Hilde Berner Hammer; Anna-Birgitte Aga; Inge Christoffer Olsen; Karl Albert Brokstad; Désirée van der Heijde; Tore K Kvien; Bjørg-Tilde Svanes Fevang; Siri Lillegraven; Espen A Haavardsholm Journal: Ann Rheum Dis Date: 2017-08-16 Impact factor: 19.103
Authors: Ling Yan; Per Bjork; Radu Butuc; Joseph Gawdzik; Judy Earley; Gene Kim; Marion A Hofmann Bowman Journal: Atherosclerosis Date: 2013-02-28 Impact factor: 5.162
Authors: Brian H Buck; David S Liebeskind; Jeffrey L Saver; Oh Young Bang; Susan W Yun; Sidney Starkman; Latisha K Ali; Doojin Kim; J Pablo Villablanca; Noriko Salamon; Tannaz Razinia; Bruce Ovbiagele Journal: Stroke Date: 2007-12-27 Impact factor: 7.914
Authors: Per Björk; Anders Björk; Thomas Vogl; Martin Stenström; David Liberg; Anders Olsson; Johannes Roth; Fredrik Ivars; Tomas Leanderson Journal: PLoS Biol Date: 2009-04-28 Impact factor: 8.029